Proton pump inhibitors: Update on their role in acid-related gastrointestinal diseases

International Journal of Clinical Practice

Volumn 59, Issue 6, 2005, Pages 709-715

  Robinson, Malcolm ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

Acid suppression; Acid related diseases; Cytochrome P450 metabolism; Gastroesophageal reflux disease; Helicobacter pylori; Non rosive reflux disease; Proton pump inhibitors

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BENATOPRAZOLE; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 2C9; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE;

CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; GENOTYPE; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STATISTICAL SIGNIFICANCE; STOMACH ACID; STOMACH PH; TASTE DISORDER; TREATMENT DURATION; DRUG ANTAGONISM; GASTROINTESTINAL DISEASE; SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASES; H(+)-K(+)-EXCHANGING ATPASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OMEPRAZOLE;

EID: 23844468166     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00517.x     Document Type: Review

References (46)

1. Majumdar SR, Soumerai SB, Farraye FA et al. Chronic acid-related disorders are common and underinvestigated. Am J Gastroenterol 2003; 98: 2409-14. 10.1111/j.1572-0241.2003.07706.x
2. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395-407. 10.1111/j.1572-0241.2000.01759.x
3. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001; 96: 303-14.
4. Brown M, Yang RD. Impact of acid-related disorders in the United States. Manag Care 2001; 10 (10 Suppl.): 7-10.
5. Henke CJ, Levin TR, Henning JM, Potter LP. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000; 95: 788-92. 10.1111/ j.1572-0241.2000.01861.x
6. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31. 10.1056/NEJM199903183401101
7. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997; 112: 1798-810.
8. Huang JQ, Hunt RH. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med 1996; 69: 159-74.
9. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors. What the practising physician needs to know. Drugs 2003; 63: 2739-54.
10. Stack WA, Knifton A, Thirlwell D et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol 1998; 93: 1909-13. 10.1111/j.1572-0241.1998.00582.x
11. Lind T, Mégaud F, Unge P et al. The MACH2 Study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-53.
12. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: Comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-14. 10.1046/ j.1365-2036.2003.01496.x
13. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators. Onset of symptom relief with rabeprazole: A community-based, open-label assessment of patients with erosive esophagitis. Aliment Pharmacol Ther 2002; 16: 445-54. 10.1046/ j.1365-2036.2002.01181.x
14. Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole. A five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20. 10.1111/ j.1572-0241.2003.08783.x
15. Andersson Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15: 1563-9. 10.1046/j.1365-2036.2001.01087.x
16. Baisley K, Warrington S, Tejura B, Morocutti A, Miller N. Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers. Gut 2002; 50 (Suppl. II): A63. (Abstract 229)
17. Warrington SJ, Tejura B, Baisley KJ, Morocutti A, Miller NM. Comparison of rabeprazole 10 mg with esomeprazole 20 mg in the control of gastric pH in healthy volunteers. Am J Gastroenterol 2001; 96 (Suppl.): S79. 10.1016/S0002-9270(01)02986-0
18. Wilder-Smith C, Claar-Nilsson C, Hasselgren G et al. Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD. Am J Gastroenterol 2001; 96 (Suppl.): S45. 10.1016/S0002-9270(01)02876-3
19. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16: 1301-7. 10.1046/j.1365-2036.2002.01292.x
20. Galmiche JP, Bruley des Varennes S, Ducrotte P et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: Effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004; 19: 655-62. 10.1111/ j.1365-2036.2004.01893.x
21. Bytzer P. On-demand therapy for gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2001; 13 (Suppl. 1): S19-S22.
22. Bytzer P, Blum AL, de Herdt D, Dubois D, on behalf of trial investigators. Six- month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004; 20: 181-8.
23. Kahrilas PJ. Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (Suppl.): S1-S9.
24. Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000; 160: 1810-6. 10.1001/ archinte.160.12.1810
25. Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003; 18: 875-92. 10.1046/j.1365-2036.2003.01771.x
26. Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 1332-9. 10.1111/ j.1572-0241.2002.05769.x
27. Johanson MF, Miner P, Jokubaitis L et al. Rabeprazole significantly improves heartburn vs placebo in endoscopically negative GERD patients with moderate to severe symptoms. Am J Gastroenterol 2001; 96 (Suppl.): S18. 10.1016/S0002-9270(01)02777-0
28. Kahrilas PJ, Miner P, Johanson L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in endoscopically negative GERD patients with frequent moderate to severe heartburn symptoms. Gastroenterology 2002; 122: A197.
29. Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (Suppl.): S40-S48.
30. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand'therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347-54. 10.1046/j.1365-2036.2001.00943.x
31. Talley NJ, Venables TL, Green JRB et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: A placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 857-63. 10.1097/00042737-200208000-00008
32. Cooper AL, Baxter G. Efficacy of lansoprazole on demand therapy in the treatment of non-erosive reflux disease and functional ulcer-like dyspepsia. Gut 2003; 52 (Suppl. VI): A137.
33. Bardhan KD, Müller-Lissner S, Bigard MA et al. Symptomatic gastro-oesophageal disease: Double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ 1999; 318: 502-7.
34. Hawkey CJ, Atherton JC, Treichel HC, Thjodleifsson B, Ravic M. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Aliment Pharmacol Ther 2003; 17: 1065-74. 10.1046/j.1365-2036.2003.01492.x
35. Gambaro C, Bilardi C, Dulbecco P et al. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: A preliminary study. Dig Liver Dis 2003; 35: 763-7. 10.1016/ S1590-8658(03)00458-4
36. Centers for Disease Control. Division of Bacterial and Mycotic Diseases. Helicobacter Pylori and peptic ulcer disease. Available at http://www.cdc.gov/ulcer/md.htm#fda. Accessed June 7, 2004.
37. Vakil N, Lanza F, Schwartz H, Barth J. Short-course PPI-based triple therapy for Helicobacter pylori eradication in the United States. Aliment Pharmacol Ther 2004; 20: 99-107. 10.1111/j.1365-2036.2004.02029.x
38. McColl KEL, Kennerley P. Proton pump inhibitors - differences emerge in hepatic metabolism. Digest Liver Dis 2002; 34: 461-7. 10.1016/ S1590-8658(02)80102-5
39. Furuta T, Shirai N, Takashima M et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple-therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 158-68. 10.1067/ mcp.2001.113959
40. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16: 1811-7. 10.1046/ j.1365-2036.2002.01348.x
41. Adachi K, Katsube T, Kawamura A et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 1259-66. 10.1046/j.1365-2036.2000.00840.x
42. Shirai N, Furuta T, Moriyama Y et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-37. 10.1046/ j.1365-2036.2001.01108.x
43. Horai Y, Kimura M, Furuie H et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001; 15: 793-803. 10.1046/j.1365-2036.2001.00980.x
44. Miyoshi M, Mizuno M, Ishiki K et al. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 2001; 16: 723-8. 10.1046/ j.1440-1746.2001.02526.x
45. Lind T, Havelund T, Lindell L et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without esophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14. 10.1046/j.1365-2036.1999.00564.x
46. Kaspari S, Kupcinskas L, Fischer R, Berghoefer P. Effective long-term management of patients suffering from mild GERD with on-demand therapy with pantoprazole 20 mg. Gut 2003; 52 (Suppl. VI): A126. 10.1136/ gut.52.1.126